Journal of Hepatology, 1990; 10: 396–399
Elsevier

Author Index (Vol. 10)

Adams, D.H. and Neuberger, J.M., Patterns of graft rejection following liver transplantation (Review), 113
Agustí, A.G.N., Roca, J., Bosch, J. and Rodriguez-Roisin, R., The lung in patients with cirrhosis (Review), 251
Alberti, A., Do single nucleotide mutations result in clinically significant changes in hepatitis B virus pathogenicity?, 268
Alexander, G.J.M., see Harrison, P.M., 332
Almdal, T.P., see Vilstrup, H., 46
Alvaro, D., Angelico, M., Gandin, C., Corradini, S.G. and Capocaccia, L., Physico-chemical factors predisposing to pigment gallstone formation in liver cirrhosis, 228
Ames, P.R., see Gaeta, G.B., 168
Angelico, M., see Alvaro, D., 228
Angeloni, A., see Bellentani, S., 356
Armocida, C., see Bellentani, S., 356
Atlan, G., see Campillo, B., 163
Attali, P., see Pelletier, G., 327

Balabaud, C., see Bioulac-Sage, P., 105
Bartolomé, F.J., Moraleda, G., Castillo, I., Martinez, M.G., Porres, J.C. and Carreño, V., Presence of HBV-DNA in peripheral blood mononuclear cells from anti-HIV symptomless carriers, 186
Bassendine, M.F., see Brind, A.M., 240
Baumgartner, U., see Schölmerich, J., 280
Bellentani, S., Armocida, C., Pecorari, M., Saccoccio, G., Marchegiano, P., Angeloni, A., Manenti, F. and Ricci, G.L., The role of calcium precipitation in the sulfoglycolithocholate-induced cholestasis of the bile fistula hamster, 356
Bendtsen, F., Henriksen, J.H., Sørensen, T.I.A. and Christensen, N.J., Effect of oral propranolol on circulating catecholamines in cirrhosis: relationship to severity of liver disease and splanchnic haemodynamics, 198
Benedetti, A., Marucci, L., Ferretti, G., Curatola, G., Jézéquel, A.M. and Orlandi, F., Evidence that plasma membrane fluidity of isolated hepatocytes is modified by exposure to microtubule-depolymerizing drugs, 144
Bianchi, L., see Stammler, L., 318
Bingle, C.D., Srai, S.K.S. and Epstein, O., Developmental changes in hepatic copper proteins in the guinea pig, 138
Biocca, M.E., see Parola, M., 341
Bioulac-Sage, P., Lafon, M.E., Saric, J. and Balabaud, C., Nerves and perisinusoidal cells in human liver (Review), 105
Bircher, J., see Lotterer, E., 284
Blum, H.E., see Hopf, U., 69
Blümel, P., see Sacher, M., 364
Bonino, F., see Brunetto, M.R., 258
Bonnet, J.C., see Campillo, B., 163
Bosch, J., see Agustí, A.G.N., 251
Boyer, J.L., see Graf, J., 387
Braga, M., see Cestari, R., 205
Brancatelli, S., see Raimondo, G., 271
Brind, A.M., McIntosh, I., Brock, D.J.H., James, O.F.W. and Bassendine, M.F., Polymerase chain reaction for detection of the alpha-1-antitrypsin Z allele in chronic liver disease, 240
Brock, D.J.H., see Brind, A.M., 240
Brú, C., see Calvet, X., 311
Bruguera, M., see Calvet, X., 311
Bruix, J., see Calvet, X., 311
Brunetto, M.R., Stemler, M., Bonino, F., Schodel, F., Oliveri, F., Rizzetto, M., Verme, G. and Will, H., A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B, 258
Buffet, C., see Pelletier, G., 327
Burroughs, A., see Tsui, M.S., 244
Burroughs, A.K., see Cestari, R., 205

Calvet, X., Bruix, J., Brú, C., Ginés, P., Vilana, R., Solé, M., Del Carmen Ayuso, M., Bruguera, M. and Rodes, J., Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases, 311
Campillo, B., Fouet, P., Bonnet, J.C. and Atlan, G., Submaximal oxygen consumption in liver cirrhosis. Evidence of severe functional aerobic impairment, 163
Capocaccia, L., see Alvaro, D., 228
Carreño, V., see Bartolomé, F.J., 186
Castillo, I., see Bartolomé, F.J., 186
Cestari, R., Braga, M., Missale, G., Ravelli, P. and Burroughs, A.K., Haemodynamic effect of triglycyl-lysine-vasopressin (glypressin) on intravascular oesophageal variceal pressure in patients with cirrhosis. A randomized placebo controlled trial, 205
Chang, T.-T., see Lin, H.-C., 362
Chapman, R.W.G., see Iveson, T.J., 85
Cheeseman, K.H., see Parola, M., 341
Chen, T.-J., see Liaw, Y.-L., 41
Christensen, N.J., see Bendtsen, F., 198
Chu, C.-M., see Liaw, Y.-L., 41
Cnudde, A., see Geubel, A.P., 23
Consensus conference committee, The value of Doppler US in the study of hepatic hemodynamics. Consensus conference (Bologna, Italy, 12 September, 1989), 353
Cooper, P., see Wilde, J.T., 217
Corradini, S.G., see Alvaro, D., 228
Crocé, L.S., see Pasquinelli, C., 180
Curatola, G., see Benedetti, A., 144

De Groot, J., see Mesa, V.A., 35
Deinhardt, F., see Hopf, U., 69
Dejgaard, A., see Vilstrup, H., 291
Del Carmen Ayuso, M., see Calvet, X., 311
Derr, R.F., Porta, A., Larkin, E.C. and Rao, G.A., Is ethanol per se hepatotoxic?, 381
Desmaretz, C., see Van Bossuyt, H., 274
Desmet, V.J., see Volpes, R., 297
Dianzani, M.U., see Parola, M., 341
Diede, H.E., see Stremmel, W., 99
Dienes, H.P., Purcell, R.H., Popper, H. and Ponzetto, A., The significance of infections with two types of viral hepatitis demonstrated by histologic features in chimpanzees, 77
Dirix, L.Y., see Nagel, R.A., 149
Dooley, J.S., see Kaye, G.L., 337

Epstein, O., see Bingle, C.D., 138
Esposito, V., see Gaeta, G.B., 168
Etienne, J.P., see Pelletier, G., 327

Ferrant, A., see Geubel, A.P., 23
Ferrero, M.E., Marni, A. and Gaja, G., Prevention of impaired liver metabolism due to ischemia in rats. Efficacy of defibrotide administration, 223
Ferretti, G., see Benedetti, A., 144
Fevery, J., see Mesa, V.A., 35

Fischer, R., see Mütting, D., 158
Foelsch, U.R., see Lotterer, E., 284
Forbes, A., see Harrison, P.M., 332
Fouet, P., see Campillo, B., 163
Franzmann, M.-B., see Møller, S., 346
French, S.W., see Kawaharam, H., 8
Fujioka, S., see Inui, Y., 62

Gaeta, G.B., Ames, P.R., Mansi, L., Esposito, V. and Giusti, G., Amphotericin B-induced depression in the phagocytic function of the isolated rat liver and its prevention by nifedipine, 168
Gaeta, G.B., see Van Bossuyt, H., 274
Gaja, G., see Ferrero, M.E., 223
Galbraith, R.A., Heme binding to Hep G2 human hepatoma cells, 305
Gandin, C., see Alvaro, D., 228
Gerok, W., see Schölmerich, J., 280
Geubel, A.P., Cnudde, A., Ferrant, A., Latinne, D. and Rahier, J., Diffuse biliary tract involvement mimicking primary sclerosing cholangitis after bone marrow transplantation, 23
Ginés, P., see Calvet, X., 311
Giusti, G., see Gaeta, G.B., 168
Gluud, C., see Vilstrup, H., 291
Goldbach, M., see Roberts, E.A., 235
Graf, J. and Boyer, J.L., The use of isolated rat hepatocyte couplets in hepatobiliary physiology (Review), 387

Hahn, E.G., see Hayasaka, A., 17
Hannoun, S., see Pelletier, G., 327
Hansen, B.A., see Vilstrup, H., 291
Hansen, B.A., see Vilstrup, H., 46
Hardt, F., see Vilstrup, H., 291
Harrison, P.M., Hughes, R.D., Forbes, A., Portmann, B., Alexander, G.J.M. and Williams, R., Failure of insulin and glucagon infusion to stimulate liver regeneration in fulminant hepatic failure, 332
Hayasaka, A., Schuppan, D., Ohnishi, K., Okuda, K. and Hahn, E.G., Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease, 17
Hayllar, K.M., see Nagel, R.A., 149
Henriksen, J.H., see Bendtsen, F., 198
Hopf, U., Küther, D., Stemerowicz, R., Lobeck, H., Lüdtke-Handjery, A., Walter, E., Blum, H.E., Roggendorf, M. and Deinhardt, F., Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV), 69
Hossack, K.F., see Rector, W.G., 375
Hughes, R.D., see Harrison, P.M., 332

Ink, O., see Pelletier, G., 327
Inui, Y., Kawata, S., Matsuzawa, Y., Tokunaga, K., Fujioka, S., Tamura, S., Kobatake, T., Keno, Y., Odaka, H., Matsuo, T. and Tarui, S., Inhibitory effect of a new α-glucosidase inhibitor on fatty liver in Zucker fatty rats, 62
Iversen, P., see Møller, S., 346
Iveson, T.J., Ryley, N.G., Kelly, P.M.A., Trowell, J.M., McGee, J.O'D. and Chapman, R.W.G., Diclofenac associated hepatitis, 85

James, O.F.W., see Brind, A.M., 240
Jézéquel, A.M., see Benedetti, A., 144

Kalk, J.-F., see Mütting, D., 158
Kanai, S., Kitani, K. and Sato, Y., Difference in the effects of ursodeoxycholate and its taurine conjugate on the biliary excretion of sulfobromophthalein in the rat, 174
Kanatakis, S., see Karayiannis, P., 350
Karayiannis, P., Kanatakis, S. and Thomas, H.C., Anti-HBs response in seroconverting chronic HBV carriers following alpha-interferon treatment, 350
Kawaharam, H., Marceau, N. and French, S.W., Effects of chlorpromazine and low calcium on the cytoskeleton and the secretory function of hepatocytes in vitro, 8
Kawase, T., see Shiratori, Y., 51
Kawata, S., see Inui, Y., 62
Kaye, G.L., Summerfield, J.A., McIntyre, N. and Dooley, J.S., Methyl tert butyl ether dissolution therapy for common bile duct stones, 337
Kelly, P.M.A., see Iveson, T.J., 85
Kennedy, H.J., see Wilde, J.T., 217
Keno, Y., see Inui, Y., 62
Kitani, K., see Kanai, S., 174
Kobatake, T., see Inui, Y., 62
Køhler, O., see Vilstrup, H., 291
Krintel, J.J., see Vilstrup, H., 291
Kristensen, M., see Vilstrup, H., 291
Küther, D., see Hopf, U., 69

Lafon, M.E., see Bioulac-Sage, P., 105
Lai, C.-L., see Lok, A.S.F., 29
Lamelin, J.-P. and Trépo, C., The hepatitis B virus and the peripheral blood mononuclear cells: a brief review (Leader), 120
Landmann, L., see Stammler, L., 318
Larkin, E.C., see Derr, R.F., 381
Latinne, D., see Geubel, A.P., 23
Lay, C.-S., see Lin, H.-C., 362
Leaning, M.S., see Sano, A., 211
Lebrec, D., see Moreau, R., 263
Lee, F.-Y., see Lin, H.-C., 370
Lee, S.-D., see Lin, H.-C., 370
Lewis, C.E., see McCarthy, S.P., 90
Liaw, Y.-F., Chen, T.-J., Chu, C.-M. and Lin, H.-H., Acute hepatitis delta virus superinfection in patients with liver cirrhosis, 41
Lin, H.-C., Tsai, Y.-T., Lee, F.-Y., Chang, T.-T., Wang, S.-S., Lay, C.-S., Lee, S.-D. and Lo, K.-J., Systemic and portal haemodynamic changes following triglycyllysine vasopressin plus nitroglycerin administration in patients with hepatitis B-related cirrhosis, 370
Lin, H.-H., see Liaw, Y.-L., 41
Lo, K.-J., see Lin, H.-C., 370
Lobeck, H., see Hopf, U., 69
Lok, A.S.F. and Lai, C.-L., Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology, 29
Longo, G., see Raimondo, G., 271
Lotterer, E., Stiehl, A., Raedsch, R., Foelsch, U.R. and Bircher, J., Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III, 284
Lüdtke-Handjery, A., see Hopf, U., 69

Manenti, F., see Pasquinelli, C., 180
Manenti, F., see Bellentani, S, 356
Manns, M., see Sacher, M., 364
Mansi, L., see Gaeta, G.B., 168
Marceau, N., see Kawaharam, H., 8
Marchegiano, P., see Bellentani, S., 356
Marni, A., see Ferrero, M.E., 223
Martinez, M.G., see Bartolomé, F.J., 186
Marucci, L., see Benedetti, A., 144
Matsuo, T., see Inui, Y., 62
Matsuzawa, Y., see Inui, Y., 62
McCarthy, S.P., Lewis, C.E. and McGee, J.O'D., Effects of ethanol on human monocyte/macrophage lysozyme storage and release. Implications for the pathobiology of alcoholic liver disease, 90
McCormick, P.A., see Tsui, M.S., 244

McGee, J.O'D., see Iveson, T.J., 85
McGee, J.O'D., see McCarthy, S.P., 90
McIntosh, I., see Brind, A.M., 240
McIntyre, N., see Kaye, G.L., 337
Melegari, M., see Pasquinelli, C., 180
Melgaard, B., see Vilstrup, H., 291
Mesa, V.A., De Groot, J. and Fevery, J., Increase in the relative amount of bilirubin diconjugates in rat bile and serum under infusion of phthaleins and indocyanine green, 35
Missale, G., see Cestari, R., 205
Miyai, K., see Schölmerich, J., 280
Mohr, S., see Wahlländer, A., 129
Møller, S., Iversen, P. and Franzmann, M.-B., Flutamide-induced liver failure, 346
Moraleda, G., see Bartolomé, F.J., 186
Moreau, R. and Lebrec, D., Nitrovasodilators and portal hypertension (Leader), 263
Muguruma, M., see Okada, Y., 1
Mütting, D., Kalk, J.-F., Fischer, R. and Wiewel, D., Spontaneous regression of oesophageal varices after long-term conservative treatment. Retrospective study in 20 patients with alcoholic liver cirrhosis, posthepatitic cirrhosis and haemochromatosis with cirrhosis, 158

Nagel, R.A., Dirix, L.Y., Hayllar, K.M., Preisig, R., Tredger, J.M. and Williams, R., Use of quantitative liver function tests – caffeine clearance and galactose elimination capacity – after orthotopic liver transplantation, 149
Neuberger, J.M., see Adams, D.H., 113

Odaka, H., see Inui, Y., 62
Oehler, R., see Stammler, L., 318
Ohnishi, K., see Hayasaka, A., 17
Okada, Y., Usumoto, R., Muguruma, M., Shimoe, T., Sunayama, T., Yamada, G., Yamamoto, K., Yamabuki, T. and Tsuji, T., The hepatocellular expression of a carbohydrate antigen 'sialyl Lewis X' in chronic hepatitis. A novel histological marker for active hepatic necroinflammation, 1
Okuda, K., see Hayasaka, A., 17
Oliveri, F., see Brunetto, M.R., 258
Orlandi, F., see Benedetti, A., 144

Parola, M., Cheeseman, K.H., Biocca, M.E., Dianzani, M.U. and Slater, T.F., Biochemical studies on bile duct epithelial cells isolated from rat liver, 341
Pasquinelli, C., Melegari, M., Villa, E., Seidenari, M., Scaglioni, P.P., Tiribelli, C., Crocé, L.S. and Manenti, F., Detection of hepatitis B virus transcripts in patients with chronic liver disease, 180
Paumgartner, G., see Wahlländer, A., 129
Pecorari, M., see Bellentani, S., 356
Pelletier, G., Salmon, D., Ink, O., Hannoun, S., Attali, P., Buffet, C. and Etienne, J.P., Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis, 327
Phillips, M.J., see Roberts, E.A., 235
Ponzetto, A., see Dienes, H.P., 77
Popper, H., see Dienes, H.P., 77
Porres, J.C., see Bartolomé, F.J., 186
Porta, A., see Derr, R.F., 381
Portmann, B., see Harrison, P.M., 332
Preisig, R., see Nagel, R.A., 149
Preston, F.E., see Wilde, J.T., 217
Purcell, R.H., see Dienes, H.P., 77

Raedsch, R., see Lotterer, E., 284
Rahier, J., see Geubel, A.P., 23
Raimondo, G., Rodinò, G., Smedile, V., Brancatelli, S., Villari, D., Longo, G. and Squadrito, G., Hepatitis B virus (HBV) markers and HBV-DNA in serum and liver tissue of patients with acute exacerbation of chronic type B hepatitis, 271
Rao, G.A., see Derr, R.F., 381
Ravelli, P., see Cestari, R., 205
Ready, J.B., see Rector, W.G., 375
Rector, W.G., Hossack, K.F. and Ready, J.B., Nitroglycerin for portal hypertension. A controlled comparison of the hemodynamic effect of graded doses, 375
Reichen, J., see Stammler, L., 318
Ricci, G.L., see Bellentani, S., 356
Rizzetto, M., see Brunetto, M.R., 258
Roberts, E.A., Spielberg, S.P., Goldbach, M. and Phillips, M.J., Phenobarbital hepatotoxicity in an 8-month-old infant, 235
Roca, J., see Agustí, A.G.N., 251
Rodes, J., see Calvet, X., 311
Rodinò, G., see Raimondo, G., 271
Rodriguez-Roisin, R., see Agustí, A.G.N., 251
Roggendorf, M., see Hopf, U., 69
Ryley, N.G., see Iveson, T.J., 85

Saccoccio, G., see Bellentani, S., 356
Sacher, M., Blümel, P., Thaler, H. and Manns, M., Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies, 364
Salmon, D., see Pelletier, G., 327
Sano, A., Taylor, M.E., Leaning, M.S. and Summerfield, J.A., Uptake of processing of glycoproteins by isolated rat hepatic endothelial and Kupffer cells, 211
Saric, J., see Bioulac-Sage, P., 105
Sato, Y., see Kanai, S., 174
Scaglioni, P.P., see Pasquinelli, C., 180
Scheuer, P.J., see Tsui, M.S., 244
Schodel, F., see Brunetto, M.R., 258
Schuppan, D., see Hayasaka, A., 17
Schölmerich, J., Baumgartner, U., Miyai, K. and Gerok, W., Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver, 280
Schütten, H.J., see Vilstrup, H,, 291
Seidenari, M., see Pasquinelli, C., 180
Shiina, S., see Shiratori, Y., 51
Shimoe, T., see Okada, Y., 1
Shiratori, Y., Tanaka, M., Umihara, J., Kawase, T., Shiina, S. and Sugimoto, T., Leukotriene inhibitors modulate hepatic injury induced by lipopolysaccharide-activated macrophages, 51
Slater, T.F., see Parola, M., 341
Smart, H.L. and Triger, D.R., A randomised prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites, 191
Smedile, V., see Raimondo, G., 271
Solé, M., see Calvet, X., 311
Sørensen, T.I.A., see Bendtsen, F., 198
Spielberg, S.P., see Roberts, E.A., 235
Squadrito, G., see Raimondo, G., 271
Srai, S.K.S., see Bingle, C.D., 138
Stammler, L., Reichen, J., Oehler, R., Bianchi, L. and Landmann, L., Decreased hepatocellular volume and intact morphology of tight junctions in calcium deprivation-induced cholestasis. Stereological and multiple indicator dilution analysis, 318
Stemerowicz, R., see Hopf, U., 69
Stemler, M., see Brunetto, M.R., 258
Stiehl, A., see Lotterer, E., 284
Stremmel, W. and Diede, H.E., Cellular uptake of conjugated bilirubin and sulfobromophthalein (BSP) by the human hepatoma cell line Hep G2 is mediated by a membrane BSP/bilirubin binding protein, 99
Sugimoto, T., see Shiratori, Y., 51
Summerfield, J.A., see Sano, A., 211
Summerfield, J.A., see Kaye, G.L., 337
Sunayama, T., see Okada, Y., 1

Tamura, S., see Inui, Y., 62
Tanaka, M., see Shiratori, Y., 51
Tarui, S., see Inui, Y., 62
Taylor, M.E., see Sano, A., 211
Thaler, H., see Sacher, M., 364
Thomas, H.C., see Karayiannis, P., 350
Thomsen, A.Chr., see Vilstrup, H., 291
Tiribelli, C., see Pasquinelli, C., 180
Tokunaga, K., see Inui, Y., 62
Tredger, J.M., see Nagel, R.A., 149
Triger, D.R., see Smart, H.L., 191
Triger, D.R., see Wilde, J.T., 217
Trowell, J.M., see Iveson, T.J., 85
Trépo, C., see Lamelin, J.-P., 120
Tsai, Y.-T., see Lin, H.-C., 370
Tsui, M.S., Burroughs, A., McCormick, P. A. and Scheuer, P.J., Portal hypertension and hepatic sinusoidal Ulex lectin binding, 244
Tsuji, T., see Okada, Y., 1

Umihara, J., see Shiratori, Y., 51
Usumoto, R., see Okada, Y., 1

Van Bossuyt, H., Desmaretz, C., Gaeta, G.B. and Wisse, E., The role of bile acids in the development of endotoxemia during obstructive jaundice in the rat, 274
Van den Oord, J.J., see Volpes, R., 297
Verme, G., see Brunetto, M.R., 258
Vilana, R., see Calvet, X., 311
Villa, E., see Pasquinelli, C., 180
Villari, D, see Raimondo, G., 271
Vilstrup, H., Gluud, C., Hardt, F., Kristensen, M., Køhler, O., Melgaard, B., Dejgaard, A., Hansen, B.A., Krintel, J.J., Schütten, H.J. and Thomsen, A.Chr., Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis, 291
Vilstrup, H., Hansen, B.A. and Almdal, T.P., Glucagon increases hepatic efficacy for urea synthesis, 46
Volpes, R., Van den Oord, J.J. and Desmet, V.J., Adhesive molecules in liver disease. Immunohistochemical distribution of thrombospondin receptors in chronic HBV infection, 297

Wahlländer, A., Mohr, S. and Paumgartner, G., Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night, 129
Walter, E., see Hopf, U., 69
Wang, S.-S., see Lin, H.-C., 362
Wiewel, D., see Mütting, D., 158
Wilde, J.T., Cooper, P., Kennedy, H.J., Triger, D.R. and Preston, F.E., Coagulation disturbances following ascites recirculation, 217
Will, H., see Brunetto, M.R., 258
Williams, R., see Harrison, P.M., 332
Williams, R., see Nagel, R.A., 149
Wisse, E., see Van Bossuyt, H., 274

Yamabuki, T., see Okada, Y., 1
Yamada, G., see Okada, Y., 1
Yamamoto, K., see Okada, Y., 1

Journal of Hepatology, 1990; 10: 400–402
Elsevier

Subject Index (Vol. 10)

N-Acetylglucosamine, 211
Adhesion molecules, 297
Adverse drug reaction, 235
Aerobic impairment, 163
Alcohol-associated liver disease, 381
Alcoholic cirrhosis, 375
Alcoholic liver disease, 90
Alopecia, 364
Amino acid, 291
Aminopyrine breath test, 129
–, 284
Amphotericin B, 168
Antiandrogen, 346
Anti-HBe positive chronic hepatitis, 258
Anti HBs, 350
Anti-HIV symtomless carrier, 186
α-1-Antitrypsin, 240
α-1-Antitrypsin Z allele, 240
Arterial pressure, 263
Ascites recirculation, 217
Ascitic fluid, 327
ATP, 223
Autoantibodies, 364
Autoimmunity, 364
Autologous mixed lymphocyte reaction, 297
Autonomic nervous system, 375

Bile acid, 387
–, 274
Bile duct caliculi, 337
Bile duct clearance, 337
Bile duct epithelial cell, 341
Bile formation, 387
Bile salt, 129
–, 228
Biliary tract, 23
Biliary transport maximum, 174
Bilirubin, 228
Bilirubin conjugate, 228
Bilirubin diconjugate, 35
Bilirubin metabolism, 35
Binding protein, 138

Ca^{2+}, 318
Caeruloplasmin, 138
Caffeine, 129
Caffeine clearance, 149
Calcium, 356
Carbohydrate antigen, 1
Carboxyterminal cross-linking domain, 17
Cellular uptake, 99
Chenodeoxycholic acid, 284
Chimpanzees, 77
Chlorpromazine, 8
Chloleresis, 174
Cholestasis, 356
–, 23
–, 280
–, 318
Cholic acid, 284
Chronic graft-versus-host disease, 23
Chronic hepatitis, 1
Chronic hepatitis B virus, 29
–, 350
Chronic hepatitis non-A, non-B, 69
Chronic liver disease, 17
–, 180
–, 240
Chronic posttransfusion hepatitis non-A, non-B, 69
Circulating antibodies, 69
Circulating catecholamine, 198
–, 198
Cirrhosis, 263
–, 41
–, 129
–, 158
–, 198
–, 251
Clinical signs, 327
Coagulation, 217
Colchicine, 144
Common bile duct stones, 337
Conjugated bilirubin, 99
Copper, 138
Cytochrome *P*-450, 341
Cytoskeleton, 387

Defibrotide, 223
Diclofenac-associated hepatitis, 85
Dissolution therapy, 337
Diuretic refractory sites, 191
Doppler ultrasound, 353
Doppler US flowmetry, 353
Doppler, clinical applications, 353
Drive therapy, 205
Drug metabolism, 235
Drug reaction, 346
Drug-induced hepatitis, 235

Encephalopathy, 291
Endotoxemia, 274
Esophageal varices, 375
Ethanol, 90
–, 381
Ethanol hepatotoxicity, 381
Etiology (HBV infection), 29
Fluidity, 144
Flutamide, 346

D-Galactosamine, 51
Galactose elimination capacity, 149
–, 284
Gap junction, 387
Glucagon, 46
–, 332
α-Glucosidase inhibitor, 62
Glucose-6-phosphatase, 341
γ-Glutamyl transpeptidase, 341
Glycoprotein, 211
Graft rejection pattern, 113
GSH peroxidase, 341
GSH transferase, 341

0168-8278/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division)

Hamster, 356
Heme receptor, 305
Heme uptake, 305
Hemodynamics, 263
Hep G2 cell, 99
Hepatic adverse reaction, 346
Hepatic efficacy, 46
Hepatic endothelial cell, 211
Hepatic function, 129
Hepatic injury, 51
Hepatic venous pressure, 263
Hepatic venous pressure gradients, 244
Hepatitis, 364
Hepatitis, diclofenac-associated, 85
Hepatitis B virus, 120
–, 180
–, 268
–, 297
Hepatitis B virus DNA, 186
–, 271
Hepatitis B virus exacerbations, 271
Hepatitis B virus markers, 271
Hepatitis B virus pathogenicity, 268
Hepatitis B virus, new strain, 258
Hepatitis B-related cirrhosis, 362
Hepatitis delta virus, 41
Hepatitis non-A, non-B, 69
Hepatocellular carcinoma, 311
Hepatocyte, 8
–, 144
Hepatocyte couplet, 387
Hepatoma, 395
Hepato-pulmonary syndrome, 251
Hepatotoxicity, 235
Histological features, 77
Histological marker, 1
HLA-DR antigen, 297
Human liver, 105

IgM anti-HBc titre elevation, 271
Immunohistochemistry, 297
Immunology, 297
Immunosuppression, 364
In vitro challenge, 235
Incidence (HBV infection), 29
Infection significance, 77
Insulin, 332
Interferon-α treatment, 350
Intrahepatic bile duct involvement, 23
Intravenous albumin, 191
Ischemia, 223

Jaundice, 274

K^+, 318
Kupffer cell, 168
–, 211
–, 274

Latex beads, 168
Leukotriene inhibitor, 51
Lipopolysaccharide, 274
Lipopolysaccharide-activated macrophage, 51
Liver, 144
–, 223
–, 280
Liver cell, 305
Liver cirrhosis, 228
Liver disease, 297
Liver failure, 332
–, 346
Liver function, 291
Liver function test, 149
Liver impairment, 163
Liver regeneration, 332
Liver transplantation, 113
–, 149
LKM antibodies, 364
Low calcium, 8
Low interferon response, 258
Lung, 251
Lysozyme accumulation, 90

Mannose, 211
Membrane sulfobromphthalein/bilirubin binding protein, 99
Membrane transport, 387
Metabolism, 223
Metallothionein, 138
Methyl tert butyl ether, 337
Microtubule, 144
Monocyte, 90
Monocyte-derived macrophage, 90
Mortality, 327

Natural history of hepatocellular carcinoma, 311
Necroinflammation, 1
Necrosis, 41
Nerves, 105
Neutrocytic ascites, 327
Nifedipine, 168
Nitrogen homeostasis, 46
Nitroglycerin, 263
–, 362
–, 375
Norepinephrine, 375

Oesophageal varices, 158
–, 205
Oral β-blockade, 198
Organic anions, 35
Oxygen consumption, 163

P450, 364
Paracentesis, 191
Patient management, 113
Perfused rat liver, 168
Peripheral blood mononuclear cell, 120
–, 186
Perisinusoidal cell, 105
Phagocytosis, 168
Phenobarbital, 235
Phosphatidylcholine, 228
Physiopathology, 205
Pigment gallstone, 228
Plasma membrane, 144
Polymerase chain reaction, 240
Polymorphonuclear cell, 327
Portal hemodynamics, 375
Portal hypertension, 205
–, 217
–, 244
–, 362
Portal pressure, 263
Portal vein, 375
Predisposing factors (HBV infection), 29
Primary biliary cirrhosis, 284

Primary sclerosing cholangitis, 23
Procollagen type III, 17
Procollagen type IV, 17
Propranolol, 198
Prostaglandin I_2, 223
Pulmonary gas exchange, 251

Rat, 280
Rat bile, 35
Rat serum, 35
Recirculation, 191
Reperfusion, 223

Saliva, 129
Secretion, 8
Serum concentration, 17
Sialyl Lewis X, 1
Single nucleotide mutations, 268
Sinusoidal alteration, 244
Sorbitol clearance, hepatic, 284
Sorbitol clearance, renal, 284
Splanchnic hemodynamics, 198
  –, 353
Spontaneous bacterial peritonitis, 327
Spontaneous regression, 158
Sporadic hepatitis non-A, non-B, 69
Steatosis, 62
Sulfobromophthalein, 99
  –, 174
Sulfoglycolithocholate, 356
Superoxide dismutase, 138
Survival, 311
Systemic hemodynamics, 362

Taurolithocholate, 280
Tauroursodeoxycholate, 174
  –, 280
Thrombospondin, 297
Tight junction, 387
  –, 318
Toxicity, 280
Transcription, 180
Treatment of cirrhosis, 291
Triglycyllysine vasopressin, 362

Ulex europaeus 1 lectin, 244
Urea synthesis, 46
Ursodeoxycholate, 174
Ursodeoxycholic acid, 274
Ursodeoxycholic acid treatment, 284

Vesicular transport, 387
Vincristine, 144
Viral hepatitis, 77
Virus genome sequence variation, 258
Volume regulation, 318

Wilson's disease, 138

Zucker fatty rats, 62